glp 1 autoimmune disease GLP1, GIP & Inflammation:What Semaglutide & Tirzepatide Really Do The anti-inflammatory and immunological properties
Description
No compounded GLP-1s
The triple-agonist mechanism, particularly the glucagon component driving preferential fat oxidation, appears to shift the ratio toward greater fat selectivity
Acknowledgments I thank Dr Nasr Elsayed Nasr and Clare Wishart for carrying out the cAMP assays in Figure 2 and Dr Suleiman Al-Sabah for carrying out the competition binding assays in Table 1
Effect of metformin vs placebo on invasive disease-free survival in patients with breast cancer: the MA.32 randomized clinical trial
About 44% of users described at least one known side effect, most commonly symptoms of gastrointestinal distress
N Engl J Med 389(24):22212232
